Payment overview · 2025
General Payments
$1,147.99
63 reported records · 21 companies
Healthcare provider profile · identity verified
William M Handy, MD
Allopathic & Osteopathic Physicians|Family Medicine · ABINGDON, VA · NPI 1124017744
Verified facts
What the public records show
CMS Open Payments records show William M Handy, MD received $1,147.99 in general payments during 2025 across 63 reported records.
Lilly USA, LLC accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Apretude, Gemtesa, Jardiance, Mounjaro, Nexletol, Paxlovid, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Prolia by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 400 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trintellix by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APRETUDE as an associated drug or biological on 20350 records involving 6296 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Apretude by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $187.68 | 16.4% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $156.59 | 13.6% | 14 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $111.03 | 9.7% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $91.40 | 8.0% | 5 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $85.43 | 7.4% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $63.72 | 5.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $58.19 | 5.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.88 | 4.3% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $41.72 | 3.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.31 | 3.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.93 | 3.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.30 | 2.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $32.13 | 2.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.42 | 2.6% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $29.11 | 2.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.98 | 2.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.91 | 2.0% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.50 | 1.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.66 | 1.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.03 | 1.3% | 1 | 2025 |
| Advanced Oxygen Therapy Inc. | Unresolved — no canonical attribution shown | $9.07 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,147.99 | 63 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $160.26 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $111.03 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $91.40 | 5 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $85.43 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $80.88 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $75.71 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $75.71 | 5 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $63.72 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $58.19 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.88 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $41.72 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $36.31 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.26 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.93 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $32.13 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.42 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $29.11 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.42 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.50 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| Topical Oxygen Chamber for extremities Normalized: topical oxygen chamber for extremities |
Device | Advanced Oxygen Therapy Inc. | $9.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 126 | exact normalized | Medicare Part D |
| APRETUDE apretude |
2025 | Apretude | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 278 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
106 | 25 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
22 | 15 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
71 | 71 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
36 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
278 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
215 | 33 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
177 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
126 | 124 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
400 | 80 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | APRETUDE open payments reported associated product |
CMS Open Payments — General Payments 20350 supporting records · 6296 recipient NPIs · example record 1189508910 |
Apretude · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1233 | 256 |
| Pantoprazole Sodium | Pantoprazole Sodium | 799 | 212 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 761 | 218 |
| Atorvastatin Calcium | Atorvastatin Calcium | 720 | 204 |
| Amlodipine Besylate | Amlodipine Besylate | 630 | 169 |
| Duloxetine Hcl | Duloxetine Hcl | 573 | 120 |
| Prednisone | Prednisone | 571 | 298 |
| Metoprolol Succinate | Metoprolol Succinate | 558 | 151 |
| Omeprazole | Omeprazole | 499 | 142 |
| Metformin Hcl | Metformin Hcl | 498 | 141 |
| Lisinopril | Lisinopril | 494 | 139 |
| Famotidine | Famotidine | 434 | 112 |
| Tamsulosin Hcl | Tamsulosin Hcl | 423 | 122 |
| Pravastatin Sodium | Pravastatin Sodium | 402 | 99 |
| Meloxicam | Meloxicam | 401 | 106 |
| Eliquis | Apixaban | 400 | 80 |
| Montelukast Sodium | Montelukast Sodium | 392 | 96 |
| Losartan Potassium | Losartan Potassium | 352 | 111 |
| Furosemide | Furosemide | 350 | 104 |
| Metoprolol Tartrate | Metoprolol Tartrate | 336 | 124 |
| Tramadol Hcl | Tramadol Hcl | 321 | 65 |
| Trazodone Hcl | Trazodone Hcl | 321 | 76 |
| Atenolol | Atenolol | 282 | 74 |
| Mounjaro | Tirzepatide | 278 | 52 |
| Potassium Chloride | Potassium Chloride | 276 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 275 | 67 |
| Ezetimibe | Ezetimibe | 259 | 74 |
| Quetiapine Fumarate | Quetiapine Fumarate | 241 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 224 | 57 |
| Chlorthalidone | Chlorthalidone | 216 | 55 |
| Trulicity | Dulaglutide | 215 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 210 | 58 |
| Sertraline Hcl | Sertraline Hcl | 205 | 42 |
| Gabapentin | Gabapentin | 202 | 44 |
| Bupropion Xl | Bupropion Hcl | 198 | 54 |
| Donepezil Hcl | Donepezil Hcl | 198 | 46 |
| Glimepiride | Glimepiride | 189 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 64 |
| Fluticasone Propionate | Fluticasone Propionate | 186 | 66 |
| Benazepril Hcl | Benazepril Hcl | 184 | 37 |
| Azithromycin | Azithromycin | 179 | 130 |
| Ozempic | Semaglutide | 177 | 38 |
| Carvedilol | Carvedilol | 176 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 174 | 63 |
| Torsemide | Torsemide | 169 | 48 |
| Amitriptyline Hcl | Amitriptyline Hcl | 162 | 44 |
| Celecoxib | Celecoxib | 159 | 43 |
| Allopurinol | Allopurinol | 158 | 36 |
| Buspirone Hcl | Buspirone Hcl | 157 | 39 |
| Alendronate Sodium | Alendronate Sodium | 149 | 46 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 141 | 43 |
| Cilostazol | Cilostazol | 139 | 31 |
| Memantine Hcl | Memantine Hcl | 134 | 20 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 126 | 124 |
| Aripiprazole | Aripiprazole | 126 | 26 |
| Baclofen | Baclofen | 125 | 30 |
| Finasteride | Finasteride | 120 | 37 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 120 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 119 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 118 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 117 | 61 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 117 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 117 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 115 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 113 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 108 | 23 |
| Metformin Hcl Er | Metformin Hcl | 106 | 24 |
| Synthroid | Levothyroxine Sodium | 106 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 106 | 28 |
| Cephalexin | Cephalexin | 105 | 63 |
| Amoxicillin | Amoxicillin | 104 | 79 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 103 | 24 |
| Mirtazapine | Mirtazapine | 99 | 23 |
| Xarelto | Rivaroxaban | 98 | 20 |
| Levetiracetam | Levetiracetam | 97 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 96 | 40 |
| Sucralfate | Sucralfate | 96 | 28 |
| Fluconazole | Fluconazole | 93 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 16 |
| Pregabalin | Pregabalin | 89 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 84 | 16 |
| Spironolactone | Spironolactone | 82 | 24 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 79 | 44 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 78 | 21 |
| Lovastatin | Lovastatin | 75 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 75 | 57 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 25 |
| Enalapril Maleate | Enalapril Maleate | 73 | 16 |
| Clonazepam | Clonazepam | 72 | suppressed |
| Fenofibrate | Fenofibrate | 72 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 18 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 71 | 71 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 18 |
| Cefdinir | Cefdinir | 70 | 52 |
| Methocarbamol | Methocarbamol | 70 | 27 |
| Topiramate | Topiramate | 67 | 16 |
| Lorazepam | Lorazepam | 63 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 62 | 14 |
| Myrbetriq | Mirabegron | 62 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 61 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 60 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 14 |
| Alprazolam | Alprazolam | 59 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 58 | 17 |
| Linzess | Linaclotide | 57 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | 15 |
| Valacyclovir | Valacyclovir Hcl | 56 | 23 |
| Colchicine | Colchicine | 55 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 17 |
| Estradiol | Estradiol | 55 | 16 |
| Jardiance | Empagliflozin | 55 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | 13 |
| Risperidone | Risperidone | 55 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 55 | 38 |
| Primidone | Primidone | 54 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 16 |
| Lansoprazole | Lansoprazole | 53 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 52 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | suppressed |
| Nitroglycerin | Nitroglycerin | 50 | 44 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 49 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 34 |
| Promethazine Hcl | Promethazine Hcl | 46 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 46 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 46 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 44 | 21 |
| Lamotrigine | Lamotrigine | 43 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 26 |
| Terazosin Hcl | Terazosin Hcl | 43 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 43 | 25 |
| Irbesartan | Irbesartan | 42 | suppressed |
| Naproxen | Naproxen | 42 | 11 |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 41 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 40 | 13 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 39 | suppressed |
| Clotrimazole | Clotrimazole | 39 | 29 |
| Digoxin | Digoxin | 39 | suppressed |
| Metronidazole | Metronidazole | 39 | 25 |
| Modafinil | Modafinil | 39 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 39 | 15 |
| Folic Acid | Folic Acid | 38 | suppressed |
| Methotrexate | Methotrexate Sodium | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 12 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 15 |
| Meclizine Hcl | Meclizine Hcl | 36 | 25 |
| Nystatin | Nystatin | 36 | 16 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 25 |
| Rivastigmine | Rivastigmine | 35 | suppressed |
| Lubiprostone | Lubiprostone | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Klor-Con M20 | Potassium Chloride | 30 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 30 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Carbamazepine | Carbamazepine | 29 | 11 |
| Diazepam | Diazepam | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 11 |
| Nexletol | Bempedoic Acid | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 27 | suppressed |
| Clonidine | Clonidine | 27 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 26 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 25 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 25 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 23 | 21 |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Prolia | Denosumab | 22 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Buprenorphine | Buprenorphine | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 13 |
| Niacin Er | Niacin | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Ursodiol | Ursodiol | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 16 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Advocate Syringes | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Apretude | Cabotegravir | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Cymbalta | Duloxetine Hcl | 12 | suppressed |
| Fluorouracil | Fluorouracil | 12 | 12 |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tracleer | Bosentan | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Tudorza Pressair | Aclidinium Bromide | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,147.99 · 63 records | Lilly USA, LLC | ABRYSVO, APRETUDE, Auvelity, CAPLYTA, COMIRNATY, Cologuard Collection Kit, EVENITY, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, INSPIRE, JARDIANCE, LEQVIO, LYBALVI, MOUNJARO, NEXLETOL, NURTEC ODT, PAXLOVID, PREVNAR 20, QULIPTA, REXULTI, TRELEGY ELLIPTA, TRINTELLIX, Topical Oxygen Chamber for extremities, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error